NCT04613674View on ClinicalTrials.gov

A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

PHASE3CompletedINTERVENTIONAL

Enrollment

441

Participants

Timeline

Start Date

December 9, 2020

Primary Completion Date

September 14, 2023

Study Completion Date

March 5, 2024

Conditions

Triple Negative Breast Cancer

Interventions

DRUG

Camrelizumab Plus Chemotherapy

camrelizumab+chemotherapy

DRUG

placebo+chemotherapy

Trial Locations (1)

Unknown

Fudan University Cancer Hospital, Shanghai

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04613674 - A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | Biotech Hunter | Biotech Hunter